Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Alvan

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Pharmacokinetics|March 1, 1978
Individual differences in the disposition of drugs metabolised in the bodyG Alvan
Lancet (London, England)|December 27, 1975
Letter: Phenytoin dosage nomogramL Lund, G Alvan
Lakartidningen|April 28, 1993
[Investigations of drugs from regional centers]P M Persson, G Alvan
European Journal of Clinical Pharmacology|January 1, 1989
Criteria for the choice and definition of healthy volunteers and or patients for phase I and phase II studies in drug development. Commentary on an action for cooperative researchP R Bechtel, G Alvan
Research Communications in Chemical Pathology and Pharmacology|March 1, 1984
Imbalance between alpha- and beta-adrenoceptor binding sites in marker cells in cystic fibrosisK Tawara, G Alvan, B Strandvik
Clinical Pharmacokinetics|March 1, 1979
Concentration dependent plasma protein binding of salicylate in rheumatoid patientsR Ekstrand, G Alvan, O Borga
Pharmacogenetics|October 1, 1996
Formation of meprobamate from carisoprodol is catalysed by CYP2C19P Dalén, G Alvan, M Wakelkamp, et al.
European Journal of Clinical Pharmacology|January 1, 1974
Pharmacokinetics of single and multiple doses of phenytoin in manL Lund, G Alvan, A Berlin, et al.
Therapeutic Drug Monitoring|August 1, 1994
Carisoprodol elimination in humansH Olsen, E Koppang, G Alvan, et al.
Lancet (London, England)|February 6, 1982
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylationG Alvan, C von Bahr, P Seidemann, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Pharmacokinetics|March 1, 1978
Individual differences in the disposition of drugs metabolised in the bodyG Alvan
Lancet (London, England)|December 27, 1975
Letter: Phenytoin dosage nomogramL Lund, G Alvan
Lakartidningen|April 28, 1993
[Investigations of drugs from regional centers]P M Persson, G Alvan
European Journal of Clinical Pharmacology|January 1, 1989
Criteria for the choice and definition of healthy volunteers and or patients for phase I and phase II studies in drug development. Commentary on an action for cooperative researchP R Bechtel, G Alvan
Research Communications in Chemical Pathology and Pharmacology|March 1, 1984
Imbalance between alpha- and beta-adrenoceptor binding sites in marker cells in cystic fibrosisK Tawara, G Alvan, B Strandvik
Clinical Pharmacokinetics|March 1, 1979
Concentration dependent plasma protein binding of salicylate in rheumatoid patientsR Ekstrand, G Alvan, O Borga
Pharmacogenetics|October 1, 1996
Formation of meprobamate from carisoprodol is catalysed by CYP2C19P Dalén, G Alvan, M Wakelkamp, et al.
European Journal of Clinical Pharmacology|January 1, 1974
Pharmacokinetics of single and multiple doses of phenytoin in manL Lund, G Alvan, A Berlin, et al.
Therapeutic Drug Monitoring|August 1, 1994
Carisoprodol elimination in humansH Olsen, E Koppang, G Alvan, et al.
Lancet (London, England)|February 6, 1982
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylationG Alvan, C von Bahr, P Seidemann, et al.
Pageof 2